Pacira Pharmaceuticals Inc (PCRX) is Initiated by Mizuho to Buy, Price Target at $79

Pacira Pharmaceuticals Inc (PCRX) was Initiated by Mizuho to “Buy” and the brokerage firm has set the Price Target at $79. Mizuho advised their investors in a research report released on Apr 19, 2016.

Many Wall Street Analysts have commented on Pacira Pharmaceuticals Inc. Pacira Pharmaceuticals Inc was Upgraded by BofA/Merrill to ” Buy” on Jan 29, 2016.

On the company’s financial health, Pacira Pharmaceuticals Inc reported $0.20 EPS for the quarter, missing the analyst consensus estimate by $ -0.08 based on the information available during the earnings call on Feb 25, 2016. Analyst had a consensus of $0.28. The company had revenue of $69.32 million for the quarter, compared to analysts expectations of $68.40 million. The company’s revenue was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.35 EPS.

Pacira Pharmaceuticals Inc closed down -0.61 points or -0.94% at $63.95 with 4,83,353 shares getting traded on Monday. Post opening the session at $64.07, the shares hit an intraday low of $62.91 and an intraday high of $65.323 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Feb 22, 2016, Paul J Hastings (director) sold 3,000 shares at $60.00 per share price. According to the SEC, on Feb 1, 2016, Scott Braunstein (SVP, Strategy & Corp. Dev.) purchased 2,000 shares at $58.92 per share price. On Jan 29, 2016, James B Jones (SVP & Chief Medical Officer) purchased 500 shares at $62.50 per share price, according to the Form-4 filing with the securities and exchange commission.

Pacira Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the development commercialization and manufacture of pharmaceutical products based on its DepoFoam drug delivery technology primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the company’s lead product candidate EXPAREL a liposome injection of bupivacaine an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL DepoFoam is also the basis for its other commercial product DepoCyt(e) which the Company manufactures for its commercial partners as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Pacira Pharmaceuticals Inc

Leave a Reply

Pacira Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pacira Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.